Ditch Partners With The CRIQ, Investissement Québec's World-Renowned Laboratory, For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc.’s partnership with the CRIQ led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais and Pharmacologist Mehdi El Hassani, will serve the objective of characterizing the aerosol generated by the DitchPen™. The company intends to present a toxicology report to the FDA and Health Canada in order to receive a Clinical Trial Authorization (Health Canada) and an Investigational New Drug approval (FDA).

Ditch Completes Successful Integration And Testing Of Its Second-Generation Alpha Product, Ready For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc. completing the successful integration and testing of its second-generation alpha product marks a green status for the upcoming nonclinical testing. The new alpha prototypes led by Co-Founder and CTO Olivier Bourbonnais and Hardware Expert François Bélanger include newer designs optimized for manufacturing along with a more effective mechanism allowing the device to be more accurate.

Ditch Partners Up With The Computer Research Institute of Montréal (CRIM) To Develop Its Treatment Algorithms

MONTREAL, QC/December, 2021 – The partnership of Ditch Labs, Inc. with the CRIM to develop its treatment algorithms led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Software Director Étienne Bélanger and Researcher Gabrielle Toupin, will strengthen the cybersecurity of its solutions and allow the company to develop algorithms based on the data it collects from the DitchPen™ and from the DitchApp™, among other important aspects.